Patents Assigned to Development Center for Biotechnology
  • Patent number: 11085062
    Abstract: A process for modifying glycoproteins is provided. The invention also provides a process for producing glycoprotein-payload conjugates, as well as the conjugates produced thereby.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: August 10, 2021
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Shih-Chong Tsai, Chun-Chung Lee, Meng-Sheng Lee, Ching-Yao Chen, Shih-Hsien Chuang, Yi-Jen Chen, Win-Yin Wei
  • Publication number: 20210139592
    Abstract: An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 2-4, 6-8, 10-12, 14-16, or 18-20; and/or a light chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 22-24, 26-28, 30-32, 34-36, or 38-40, wherein the antibody is a chimeric, humanized, composite, or human antibody.
    Type: Application
    Filed: July 14, 2019
    Publication date: May 13, 2021
    Applicant: Development Center for Biotechnology
    Inventors: Cheng-Chou YU, Shih-Rang YANG, Tsung-Han HSIEH, Mei-Chi CHAN, Shu-Ping YEH, Chuan-Lung HSU, Ling-Yueh HU, Chih-Lun HSIAO
  • Patent number: 10980853
    Abstract: The present invention provides a process for the preparation of a Crassocephalum crepidioides extract, and the extract prepared thereby. The present invention further relates to a pharmaceutical composition/combination comprising the Crassocephalum crepidioides extract. The use of the extract and the composition/combination comprising the extract in the prevention or treatment of cancer is also provided.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: April 20, 2021
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Dai-Hua Tsai, Tzung Hsien Lai, Tsui Hsu Chan, Yuh Shan Chung, Li-Chuan Hsu
  • Patent number: 10947316
    Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab?(L?D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: March 16, 2021
    Assignee: Development Center for Biotechnology
    Inventors: Chao-Pin Lee, Shih-Hsien Chuang, Chuan-Lung Hsu, Yi-Jen Chen, Yu-Chin Nieh, Win-Yin Wei, Chia-Cheng Wu
  • Publication number: 20210052719
    Abstract: An antigenic short peptide includes 11 to 15 amino-acid residues and has an ability to induce antibody against influenza virus. The sequence of the antigenic peptide is selected from hemagglutinin (HA). The antigenic peptide includes the sequence of JJ (SEQ ID NO:2), JJ-1 (SEQ ID NO:3), JJ-2 (SEQ ID NO:4), JJ-3 (SEQ ID NO:5) or JJ-4 SEQ ID NO:6). A method for inducing a broad-spectrum immunity against influenza viruses includes administering a vaccine to a subject, wherein the vaccine comprises one of the above antigenic peptide.
    Type: Application
    Filed: December 29, 2017
    Publication date: February 25, 2021
    Applicant: Development Center for Biotechnology
    Inventors: Jia-Ming CHANG, Wan-Jyun WEI
  • Publication number: 20210015942
    Abstract: An immunoconjugate having the Formula Ab-[L1-(A-L2-B)m]n, wherein: (a) Ab is an antibody or a binding fragment thereof; (b) L1 and L2 are each independently a linker, wherein L1 and L2 are the same or different and wherein L1 links to L2; (c) A is a target-protein ligand/binder; (d) B is a ubiquitin ligase ligand/binder, and (e) n and m are independently integers from 1 to 8. The target protein includes kinase, G protein-coupled receptors, transcription factor, phosphatases, and RAS superfamily members.
    Type: Application
    Filed: January 9, 2019
    Publication date: January 21, 2021
    Applicant: Development Center for Biotechnology
    Inventors: Shih-Hsien Chuang, Chu-Bin Liao, Wei-Ting Sun, Chen-Hsien Liang, Wun-Huei Lin, Chun-Liang Lai, Her-Sheng Lin
  • Publication number: 20210009597
    Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.
    Type: Application
    Filed: December 26, 2018
    Publication date: January 14, 2021
    Applicant: Development Center for Biotechnology
    Inventors: Shih-Chieh YEN, Chu-Bin LIAO, Hui-Chen WANG, Po-Ting CHEN, Yu-Chih PAN, Tsung-Hui LI, Bo-Rong CHEN, Shian-Yi CHIOU
  • Patent number: 10793542
    Abstract: The present invention provides a compound of formula (1): wherein X, Y, Z1, Z2, R1, R2, A, B, p and q are as disclosed in the specification. A pharmaceutical composition and a method for modulating the Hedgehog pathway are also provided. The present invention rurthe r provides a process for preparing the compound.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: October 6, 2020
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Mann-Yan Kuo, Ying-Shuan Lee, Yann-Yu Lu, Chia-Wei Liu, Seline Hsieh, Ju-Ying Yang
  • Patent number: 10781266
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 22, 2020
    Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Po-Yin Lin, Ya-Wei Tsai, Chao-Yang Huang, Ying-Yung Lok, Chung-Hsiun Wu, Hsien-Yu Tsai, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
  • Patent number: 10781265
    Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX?SGNRRYZLV (SEQ ID NO:7, wherein X? is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: September 22, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Chia-Cheng Wu, Szu-Liang Lai, Yu-Jung Chen, Chih-Yung Hu, Tzu-Yin Lin
  • Patent number: 10752688
    Abstract: An anti-human T-cell immunoglobulin domain and mucin domain 3 (TIM-3) antibody, can bind the peptides, comprising the amino-acid sequence RKGDVSL (SEQ ID NO: 9) and/or EKFNLKL (SEQ ID NO: 10) of human TIM-3 protein. The antibody can regulate immune cell activity. The antibody or binding fragment thereof is useful in diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface TIM-3 such as lung, liver, esophageal cancer and solid tumors.
    Type: Grant
    Filed: December 30, 2017
    Date of Patent: August 25, 2020
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Yu-Chen Yang, Li-Yu Chen, Chia-Hua Li, Pei-Han Tai, Hong-Kai Chen, Ying-Yung Lok, Chih-Yung Hu, Chien-Tsun Kuan, Chung-Hsiun Wu
  • Patent number: 10745360
    Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: August 18, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Nan-Horng Lin, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Mann-Yan Kuo
  • Patent number: 10689362
    Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: June 23, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Shao-Zheng Peng, Chu-Bin Liao, Hung-Kai Chen, Chen-Hsuan Ho, Hung-Jyun Huang, Shian-Yi Chiou
  • Patent number: 10624962
    Abstract: A detoxified recombinant E. coli heat-labile enterotoxin mutant, LTS61K, is employed as a carrier protein to conjugate polysaccharide. The LTS61K contains a mutated mature sub-unit A (LTA) that includes lysine at amino acid position 61 and a wild-type mature sub-unit B (LTB). Various types of bacterial capsular polysaccharide antigens were chemically conjugated with the LTS61K protein by a reductive amination reaction. The conjugated polysaccharide-LTS61K products were physically, chemically and biochemically identified as soluble form. Rabbits were immunized intramuscularly to determine the immunogenicity of conjugated vaccines by ELISA to detect anti-polysaccharide antigen IgG titers and serum bactericidal assay thereby determining the functional activity of the antibodies. Study results show that conjugated polysaccharide-LTS61K vaccines induce higher polysaccharide-specific IgG titers and greater bactericidal activity in sera than that of polysaccharide alone or polysaccharide mixed with LTS61K.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: April 21, 2020
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Yu-Shen Hsu, I-Ling Kou, Kuo-Chan Hung, Yuan-Hsin Lu, Ta-Tung Yuan
  • Publication number: 20200087697
    Abstract: A process for modifying glycoproteins is provided. The invention also provides a process for producing glycoprotein payload conjugates, as well as the conjugates produced thereby.
    Type: Application
    Filed: December 29, 2017
    Publication date: March 19, 2020
    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: SHIH-CHONG TSAI, CHUN-CHUNG LEE, MENG-SHENG LEE, CHING-YAO CHEN, SHIH-HSIEN CHUANG, YI-JEN CHEN, WIN-YIN WEI
  • Patent number: 10588909
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: March 17, 2020
    Assignees: Taivex Therapeutics Corporation, Development Center For Biotechnology
    Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
  • Publication number: 20200079753
    Abstract: The present invention provides a compound of formula (I) wherein X, Y, Z1, Z2, R1, R2, A, B, p and q are as disclosed in the specification. A pharmaceutical composition and a method for modulating the Hedgehog pathway are also provided. The present invention further provides a process for preparing the compound.
    Type: Application
    Filed: November 22, 2017
    Publication date: March 12, 2020
    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: MANN-YAN KUO, YING-SHUAN LEE, YANN-YU LU, CHIA-WEI LIU, SELINE HSIEH, JU-YING YANG
  • Publication number: 20200062738
    Abstract: A compound for inhibiting BMI-1/MCL-1 having a structure of Formula (I), wherein the various groups are as described. A pharmaceutical composition for treating cancer includes an effective amount of a compound of Formula (I).
    Type: Application
    Filed: April 30, 2018
    Publication date: February 27, 2020
    Applicants: Development Center for Biotechnology, National Yang-Ming University
    Inventors: Cheng-Wen Wu, Erh-Hsuan Jiann Lin, Chi-Ying Huang, Jia-Ming Chang, Shih-Hsien Chuang, Hui-Jan Hsu, Wei-Wei Chen
  • Patent number: 10561700
    Abstract: The present invention is related to the use of an overground part of Hedychium coronarium Koenig in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of Hedychium coronarium Koenig and its use in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 18, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Rey Yuh Wu, Yu-Yuan Wu, Lung-Yu Kuan, Klim King
  • Publication number: 20200048365
    Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX?SGNRRYZLV (SEQ ID NO:7, wherein X? is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).
    Type: Application
    Filed: May 24, 2018
    Publication date: February 13, 2020
    Applicant: Development Center for Biotechnology
    Inventors: Chia-Cheng Wu, Szu-Liang Lai, Yu-Jung Chen, Chih-Yung Hu, Tzu-Yin Lin